348 related articles for article (PubMed ID: 31353944)
1. Immunotherapy for Cutaneous T-Cell Lymphoma: Current Landscape and Future Developments.
Sivanand A; Surmanowicz P; Alhusayen R; Hull P; Litvinov IV; Zhou Y; Gniadecki R
J Cutan Med Surg; 2019; 23(5):537-544. PubMed ID: 31353944
[TBL] [Abstract][Full Text] [Related]
2. Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part II. Prognosis, management, and future directions.
Jawed SI; Myskowski PL; Horwitz S; Moskowitz A; Querfeld C
J Am Acad Dermatol; 2014 Feb; 70(2):223.e1-17; quiz 240-2. PubMed ID: 24438970
[TBL] [Abstract][Full Text] [Related]
3. Extracorporeal photophoresis: an evidence-based analysis.
Medical Advisory Secretariat
Ont Health Technol Assess Ser; 2006; 6(6):1-82. PubMed ID: 23074497
[TBL] [Abstract][Full Text] [Related]
4. Immune evasion and current immunotherapy strategies in mycosis fungoides (MF) and Sézary syndrome (SS).
Shalabi D; Bistline A; Alpdogan O; Kartan S; Mishra A; Porcu P; Nikbakht N
Chin Clin Oncol; 2019 Feb; 8(1):11. PubMed ID: 30691274
[TBL] [Abstract][Full Text] [Related]
5. Existing and Emerging Therapies for Cutaneous T-Cell Lymphoma.
Van-de-Velde V; Zhou Y
J Cutan Med Surg; 2019; 23(3):319-327. PubMed ID: 30943788
[TBL] [Abstract][Full Text] [Related]
6. Evolving insights in the pathogenesis and therapy of cutaneous T-cell lymphoma (mycosis fungoides and Sezary syndrome).
Wong HK; Mishra A; Hake T; Porcu P
Br J Haematol; 2011 Oct; 155(2):150-66. PubMed ID: 21883142
[TBL] [Abstract][Full Text] [Related]
7. Primary cutaneous T-cell lymphomas other than mycosis fungoides and Sézary syndrome. Part II: Prognosis and management.
Oh Y; Stoll JR; Moskowitz A; Pulitzer M; Horwitz S; Myskowski P; Noor SJ
J Am Acad Dermatol; 2021 Nov; 85(5):1093-1106. PubMed ID: 33945836
[TBL] [Abstract][Full Text] [Related]
8. A new nail in the CTCL coffin.
Lessin SR
J Invest Dermatol; 2006 Nov; 126(11):2368-9. PubMed ID: 17041618
[TBL] [Abstract][Full Text] [Related]
9. Immune cell topography predicts response to PD-1 blockade in cutaneous T cell lymphoma.
Phillips D; Matusiak M; Gutierrez BR; Bhate SS; Barlow GL; Jiang S; Demeter J; Smythe KS; Pierce RH; Fling SP; Ramchurren N; Cheever MA; Goltsev Y; West RB; Khodadoust MS; Kim YH; Schürch CM; Nolan GP
Nat Commun; 2021 Nov; 12(1):6726. PubMed ID: 34795254
[TBL] [Abstract][Full Text] [Related]
10. How we treat advanced stage cutaneous T-cell lymphoma - mycosis fungoides and Sézary syndrome.
Sethi TK; Montanari F; Foss F; Reddy N
Br J Haematol; 2021 Nov; 195(3):352-364. PubMed ID: 33987825
[TBL] [Abstract][Full Text] [Related]
11. The immunopathogenesis and immunotherapy of cutaneous T cell lymphoma: Current and future approaches.
Weiner DM; Durgin JS; Wysocka M; Rook AH
J Am Acad Dermatol; 2021 Mar; 84(3):597-604. PubMed ID: 33352268
[TBL] [Abstract][Full Text] [Related]
12. Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part I. Diagnosis: clinical and histopathologic features and new molecular and biologic markers.
Jawed SI; Myskowski PL; Horwitz S; Moskowitz A; Querfeld C
J Am Acad Dermatol; 2014 Feb; 70(2):205.e1-16; quiz 221-2. PubMed ID: 24438969
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and tolerability of currently available therapies for the mycosis fungoides and Sezary syndrome variants of cutaneous T-cell lymphoma.
Whittaker SJ; Foss FM
Cancer Treat Rev; 2007 Apr; 33(2):146-60. PubMed ID: 17275192
[TBL] [Abstract][Full Text] [Related]
14. Multidisciplinary Management of Mycosis Fungoides/Sézary Syndrome.
Berg S; Villasenor-Park J; Haun P; Kim EJ
Curr Hematol Malig Rep; 2017 Jun; 12(3):234-243. PubMed ID: 28540671
[TBL] [Abstract][Full Text] [Related]
15. Cutaneous T cell lymphoma: mycosis fungoides, Sézary syndrome, and other variants.
Edelson RL
J Am Acad Dermatol; 1980 Feb; 2(2):89-106. PubMed ID: 6988470
[TBL] [Abstract][Full Text] [Related]
16. European Organisation for Research and Treatment of Cancer consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome - Update 2017.
Trautinger F; Eder J; Assaf C; Bagot M; Cozzio A; Dummer R; Gniadecki R; Klemke CD; Ortiz-Romero PL; Papadavid E; Pimpinelli N; Quaglino P; Ranki A; Scarisbrick J; Stadler R; Väkevä L; Vermeer MH; Whittaker S; Willemze R; Knobler R
Eur J Cancer; 2017 May; 77():57-74. PubMed ID: 28365528
[TBL] [Abstract][Full Text] [Related]
17. How I treat mycosis fungoides and Sézary syndrome.
Prince HM; Whittaker S; Hoppe RT
Blood; 2009 Nov; 114(20):4337-53. PubMed ID: 19696197
[TBL] [Abstract][Full Text] [Related]
18. Antibody-Based Therapies for Cutaneous T-Cell Lymphoma.
Welborn M; Duvic M
Am J Clin Dermatol; 2019 Feb; 20(1):115-122. PubMed ID: 30430444
[TBL] [Abstract][Full Text] [Related]
19. The immunopathogenesis and immunotherapy of cutaneous T cell lymphoma: Pathways and targets for immune restoration and tumor eradication.
Durgin JS; Weiner DM; Wysocka M; Rook AH
J Am Acad Dermatol; 2021 Mar; 84(3):587-595. PubMed ID: 33352267
[TBL] [Abstract][Full Text] [Related]
20. Pathogenesis and Therapy of Primary Cutaneous T-Cell Lymphoma: Collegium Internationale Allergologicum (CIA) Update 2020.
Bobrowicz M; Fassnacht C; Ignatova D; Chang YT; Dimitriou F; Guenova E
Int Arch Allergy Immunol; 2020; 181(10):733-745. PubMed ID: 32690848
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
